Literature DB >> 6402212

Diagnosis of Duchenne muscular dystrophy: experiences of parents of sufferers.

M A Firth.   

Abstract

Sixty nine parents of boys suffering from Duchenne muscular dystrophy were interviewed at home. The interview explored the parents' experiences at the time of their son's diagnosis. Many families had experienced distressing delays (average 2.5 years) between the time they first became aware of symptoms and the time of the diagnosis. On only 18 occasions were both parents told of the diagnosis together. One third of the parents were "not satisfied" with the way the diagnosis had been communicated. Parents want to know as soon as possible if there is something wrong with their child. They should be told the diagnosis together and in private. Full information should be given and a series of contacts should be arranged.

Entities:  

Mesh:

Year:  1983        PMID: 6402212      PMCID: PMC1547093          DOI: 10.1136/bmj.286.6366.700

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  MONGOLISM: WHEN SHOULD PARENTS BE TOLD?

Authors:  C M DRILLIEN; E M WILKINSON
Journal:  Br Med J       Date:  1964-11-21

2.  Mongolism: telling the parents.

Authors:  J Carr
Journal:  Dev Med Child Neurol       Date:  1970-04       Impact factor: 5.449

3.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

4.  "Twenty years a-growing.

Authors:  F Pilkington
Journal:  Br J Psychiatry       Date:  1969-01       Impact factor: 9.319

5.  Predictability of blood levels of gentamicin in man.

Authors:  M Barza; R B Brown; D Shen; M Gibaldi; L Weinstein
Journal:  J Infect Dis       Date:  1975-08       Impact factor: 5.226

  5 in total
  11 in total

1.  Imparting the diagnosis of life threatening illness in children.

Authors:  H Woolley; A Stein; G C Forrest; J D Baum
Journal:  BMJ       Date:  1989-06-17

2.  Parental Reflections on the Diagnostic Process for Duchenne Muscular Dystrophy: A Qualitative Study.

Authors:  Roxanna M Bendixen; Amy Houtrow
Journal:  J Pediatr Health Care       Date:  2016-10-12       Impact factor: 1.812

3.  A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy.

Authors:  Siaw H Wong; Belinda J McClaren; Alison Dalton Archibald; Alice Weeks; Tess Langmaid; Monique M Ryan; Andrew Kornberg; Sylvia A Metcalfe
Journal:  Eur J Hum Genet       Date:  2015-01-28       Impact factor: 4.246

4.  Screening for Duchenne muscular dystrophy.

Authors:  J Fenton-May; D M Bradley; J R Sibert; R Smith; E P Parsons; P S Harper; A Clarke
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

5.  Screening the newborn for Duchenne muscular dystrophy: parents' views.

Authors:  M A Firth; E J Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

6.  Recognising and preventing Duchenne muscular dystrophy.

Authors:  D Gardner-Medwin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

7.  Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK).

Authors:  Stuart J Moat; Donald M Bradley; Rachel Salmon; Angus Clarke; Louise Hartley
Journal:  Eur J Hum Genet       Date:  2013-01-23       Impact factor: 4.246

8.  A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy.

Authors:  Sally Lawton; Chriselle Hickerton; Alison D Archibald; Belinda J McClaren; Sylvia A Metcalfe
Journal:  Eur J Hum Genet       Date:  2014-07-30       Impact factor: 4.246

9.  Research samples from families with genetic diseases: a proposed code of conduct.

Authors:  P S Harper
Journal:  BMJ       Date:  1993-05-22

10.  Communicating the Spinal Muscular Atrophy diagnosis to children and the principle of autonomy.

Authors:  Isabella Araujo Mota Fernandes; Renata Oliveira Almeida Menezes; Guilhermina Rego
Journal:  BMC Pediatr       Date:  2022-08-17       Impact factor: 2.567

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.